Wuerzburg, Germany – June 8, 2010

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the receipt of the recommendation letter of an independent Drug Monitoring Committee to proceed with its clinical phase IIa NOSTRA trial (NO-Synthase inhibition in TRAumatic brain injury).

Recruitment of the first open cohort (8 patients) was completed on April 2nd, 2010. This cohort intended to demonstrate safety and tolerability of the applied dose in patients suffering from traumatic brain injury. The design of the following cohort will now be placebo-controlled, randomized and double blind.

About the NOSTRA trial:

The NOSTRA trial is an explorative European multicentre placebo-controlled, randomized, double blind study examining safety and tolerability as well as pharmacodynamic effects and pharmacokinetics of the compound VAS203. VAS203 is novel type of NO-synthase inhibitors competing with its co-factor tetrahydrobiopterin.

In total, 32 patients will be enrolled in three cohorts in five study centres. All study centres are routinely using the microdialysis technique which shall be instrumental to measure the NO- and energy metabolism as well as the presence of the compound in the brain tissue. The study is expected to run until the first quarter of 2011.

About vasopharm:

vasopharm is focused on the development of therapeutics which permits modulating the bioavailability of biological NO, by addressing the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm’s drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure.

Wuerzburg, Germany – March 11, 2010

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the appointment of Dr Thomas Lander to its Supervisory Board.

Thomas Lander, MD, is an independent R&D consultant to the biotech industry. He is a physician with board certification in internal medicine and diabetology. Besides he worked many years in basic research with a focus on immunology and pharmacogenetics. Thereafter he has spent 23 years in the pharmaceutical and biotech industry where he had senior management positions mainly in R&D with major international companies including Boehringer Ingelheim, NovoNordisk, Bristol-Myers Squibb, GlaxoSmithKline and Merck KGaA. Most recently, he was managing director of CureVac GmbH, Tuebingen.

Thomas Lander is also a non-executive director with Lipid Therapeutics GmbH, Heidelberg, and CT Atlantic AG, Zurich, Switzerland.